Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$90.28
$1.44(2.44%)
At close: 4:00 PM EDT
$90.28
$1.44(2.44%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous Close$60.5
Volume611.52K
Average Volume (3M)714.59K
Market Cap
$2.59B
Enterprise Value$2.07K
Total Cash (Recent Filing)$132.55M
Total Debt (Recent Filing)$167.40M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 03, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding29,822,540
10 Day Avg. Volume493,452
30 Day Avg. Volume714,591
Financial Highlights & Ratios
PEG Ratio2.86
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$82.86Price Target Upside-8.22% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.08
Revenue Forecast (FY)$481.93M
Bulls Say, Bears Say
Bulls Say
Strong Test And Revenue GrowthRapid test-volume and exome/genome revenue growth indicate expanding adoption of GeneDx’s clinical offerings. Sustained demand can improve laboratory scale, strengthen provider relationships and support operating leverage as reimbursement execution improves.
Expanding Payer CoverageBroader payer coverage expands the addressable reimbursed market and reduces a key barrier to ordering genomic tests. If coverage converts into paid claims, it can support durable collection improvement, revenue visibility and wider clinical adoption.
Healthy Gross MarginsA gross margin near 70% demonstrates attractive underlying economics for the testing platform despite current operating losses. Maintaining this level while scaling volumes would provide a solid base for future profitability once reimbursement and cost execution improve.
Bears Say
Negative Cash GenerationThe reversal from positive 2025 cash flow to substantial TTM cash burn raises funding and execution risk. Continued investment or delayed reimbursement could require additional capital before operating improvements translate into consistently self-funded growth.
Low Reimbursement CollectionsLow collection rates mean test volume is not yet translating efficiently into realized revenue and cash. Administrative barriers, denials and payer-specific workflows could keep results volatile, limiting the near-term benefit of strong clinical demand.
High Genome Testing CostsGenome testing’s materially higher unit cost creates structural pressure on blended economics as genome utilization rises. With no near-term cost reduction expected, GeneDx must improve pricing, mix and operational efficiency to protect margins during continued scaling.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $2.59B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Nov 03, 2026 which is in 60 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Aug 03, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.198.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Overvalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.07.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 29,822,540 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 4.48%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.86 (-8.22% Downside)
$82.86 (-8.22% Downside)
Blogger Sentiment
Bullish
WGS Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $11.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GeneDx Holdings
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
WGS Company Deck
WGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a cautiously optimistic outlook: strong operational performance (record test volumes, revenue growth, return to profitability, margin improvement, and major payer coverage wins) provides clear highlights, while significant near‑term challenges remain around low outpatient collection rates, higher genome unit costs, and timing lags for revenue realization. Management presented a concrete multi‑pronged plan (RCM, payer workflows, technology, commercial investments) and reinforced guidance, expecting meaningful RCM and revenue uplift beginning in Q4 2026 and more substantially in 2027.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$82.86
▼(-8.22% Downside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
46.37% Insiders
18.82% Mutual Funds
17.60% Other Institutional Investors
1.25% Public Companies and
Individual Investors